Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients

NCT03882060 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Moyamoya Disease
Pediatrics
Cerebrovascular Disorders

Interventions

DRUG: erythropoietin
DRUG: Normal saline

Sponsor

Seoul National University Hospital